CStone Pharmaceuticals (HK:2616) has released an update.
CStone Pharmaceuticals has granted exclusive promotion rights for AYVAKIT, a precision therapy for gastrointestinal stromal tumors, to Jiangsu Hengrui Pharmaceuticals in mainland China. This strategic move, combined with Hengrui’s robust commercial network, aims to maximize AYVAKIT’s market potential while CStone retains significant rights, including development and distribution. The agreement includes an upfront payment to CStone, who will continue to record AYVAKIT’s sales revenue, marking a significant step in CStone’s commitment to advancing cancer treatment.
For further insights into HK:2616 stock, check out TipRanks’ Stock Analysis page.
